Sarah Holstein, MD, PhD

Sarah Holstein, MD, PhD
Associate Professor, Internal MedicineHolsteinPP
Division of Oncology & Hematology

Academic office mailing address:
UNMC Oncology/Hematology Division
986840 Nebraska Medical Center
Omaha, NE 681980-6840

Main Academic Ph. 402-559-8500
New Patient Referral Ph. 402-559-5600
Fax. 402-559-6520

Practice location:
Fred & Pamela Buffett Cancer Center
505 South 45th Street
Omaha, NE 68105 (map)

University of Iowa Carver College of Medicine, MD, PhD (2004)
University of Iowa Internal Medicine Resident (2004-2006)
University of Iowa Hematology/Oncology Fellow (2006-2010)

Hospital Appointments:
Nebraska Medicine

Clinical, translational, and basic science research in multiple myeloma with an emphasis on the development of novel therapeutic agents.

Biographical Sketch:
Dr. Holstein is a physician-scientist who specializes in the treatment of multiple myeloma and related plasma cell dyscrasias. She is the Team Leader of the Myeloma/Plasma Cell Dyscrasia Group at the Fred and Pamela Buffett Cancer Center. Prior to joining the faculty at UNMC, Dr. Holstein served as a multiple myeloma specialist at the Roswell Park Comprehensive Cancer Center and the University of Iowa. Her laboratory is focused on gaining a better understanding of the pathophysiology of multiple myeloma and the development of novel therapeutic agents for multiple myeloma. Her laboratory research has received funding from such sources as the National Institutes of Health, the American Society of Hematology, and the PhRMA Foundation. Dr. Holstein is an active clinical investigator, and has been involved in clinical trials for patients with newly diagnosed multiple myeloma, with relapsed/refractory disease, as well as in the post-transplant maintenance setting. She has written numerous peer-reviewed research articles as well as review articles and book chapters. She has served as a member of the NCCN Multiple Myeloma Panel and currently serves on multiple other national multiple myeloma committees, including the Alliance myeloma committee. She is a member of the International Myeloma Working Group. She is an Associate Editor for Clinical Pharmacology & Therapeutics. She serves as Director of the Pilot Projects Program for the Great Plains IDeA-CTR and as co-leader of the Targets, Modulators and Delivery Program for the Buffett Cancer Center.